

Lennart Philipson Award Selection Criteria

Award Objective

The Lennart Philipson Award (LPA) is intended to recognise outstanding and validated contributions in:

“translational research and/or technology innovation across the complete spectrum of life sciences”

Please note that the LPA is not for recognition of exceptional contributions in research per se.

Selection Criteria

There are multiple areas to consider when selecting LPA nominations. These areas include:

- 1. The breadth of the innovation.** New technologies that are taken up by diverse laboratories across a range of research fields would be very strong examples. Examples to illustrate this include:
 - a. PCR,
 - b. Enhanced gene sequencing,
 - c. Gene microarrays,
 - d. Continuing development of improved microscopy,
 - e. CRISPR / Cas.

- 2. Direct links to societal benefits.** The most obvious examples are major contributions to novel drugs to treat previously poorly treated conditions. Examples to illustrate this include:
 - f. Significant contributions to the discovery and development of therapeutic antibodies or other drugs.

Secondary Factors to Distinguish Between Strong but Diverse Applications

- Is there secured IPR protection?
- For therapeutic innovation, is there proof of concept in clinical evaluation?
- For technology innovation, how has the technology been dispersed (e.g., has it been licensed to an industrial partner? How has the uptake by others been facilitated?)?